Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage?

Area of Science:

• Pediatric Nephrology
• Clinical Pharmacology
• Immunosuppression Therapy

Background:

• Tacrolimus (Tac) is an alternative immunosuppressant for childhood nephrotic syndrome, used to mitigate side effects.
• Understanding Tac pharmacokinetics (PK) is crucial due to its high protein binding and variable influencing factors.
• Limited data exists on Tac PK during active nephrotic syndrome relapse versus remission in children.

Purpose of the Study:

• To characterize and compare Tac PK profiles in children with nephrotic syndrome during relapse and remission.
• To evaluate if Tac PK differs significantly between these two clinical states.

Main Methods:

• 14 PK profiles were analyzed in 7 children with steroid-resistant nephrotic syndrome at week 1 (relapse) and week 16 (remission).
• Tac levels were measured at multiple time points post-dose (pre-dose, 0.5, 1, 2, 4, 12 hours).
• Data was compared to historical PK data from pediatric renal transplant recipients using descriptive statistics.

Main Results:

• No statistically significant differences were observed in median dose-normalized area-under-the-time-concentration profiles, peak concentrations, time to peak, or trough levels between relapse and remission.
• Individual dose-normalized Tac levels at all time points were also comparable between the two states.
• The median Tac dose was similar in both the relapse and remission phases.

Conclusions:

• Tacrolimus pharmacokinetics are unaltered during relapse of childhood nephrotic syndrome.
• These findings suggest that Tac PK is stable regardless of the nephrotic syndrome disease state (relapse or remission).
• This supports consistent dosing strategies for tacrolimus in pediatric patients with nephrotic syndrome.